197 related articles for article (PubMed ID: 7667323)
1. Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model.
Addison CL; Braciak T; Ralston R; Muller WJ; Gauldie J; Graham FL
Proc Natl Acad Sci U S A; 1995 Aug; 92(18):8522-6. PubMed ID: 7667323
[TBL] [Abstract][Full Text] [Related]
2. A double recombinant adenovirus expressing the costimulatory molecule B7-1 (murine) and human IL-2 induces complete tumor regression in a murine breast adenocarcinoma model.
Emtage PC; Wan Y; Bramson JL; Graham FL; Gauldie J
J Immunol; 1998 Mar; 160(5):2531-8. PubMed ID: 9498799
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors.
Addison CL; Bramson JL; Hitt MM; Muller WJ; Gauldie J; Graham FL
Gene Ther; 1998 Oct; 5(10):1400-9. PubMed ID: 9930346
[TBL] [Abstract][Full Text] [Related]
4. Enhanced interleukin-2 gene transfer immunotherapy of breast cancer by coexpression of B7-1 and B7-2.
Emtage PC; Wan Y; Muller W; Graham FL; Gauldie J
J Interferon Cytokine Res; 1998 Nov; 18(11):927-37. PubMed ID: 9858314
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy with interleukin-2 and wild-type p53 expressed by adenoviral vectors potentiates tumor regression in a murine model of breast cancer.
Pützer BM; Bramson JL; Addison CL; Hitt M; Siegel PM; Muller WJ; Graham FL
Hum Gene Ther; 1998 Mar; 9(5):707-18. PubMed ID: 9551618
[TBL] [Abstract][Full Text] [Related]
6. Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression.
Pützer BM; Hitt M; Muller WJ; Emtage P; Gauldie J; Graham FL
Proc Natl Acad Sci U S A; 1997 Sep; 94(20):10889-94. PubMed ID: 9380730
[TBL] [Abstract][Full Text] [Related]
7. Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models.
Emtage PC; Wan Y; Hitt M; Graham FL; Muller WJ; Zlotnik A; Gauldie J
Hum Gene Ther; 1999 Mar; 10(5):697-709. PubMed ID: 10210138
[TBL] [Abstract][Full Text] [Related]
8. Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination.
Bramson JL; Hitt M; Gauldie J; Graham FL
Gene Ther; 1997 Oct; 4(10):1069-76. PubMed ID: 9415313
[TBL] [Abstract][Full Text] [Related]
9. Combined treatment of a murine breast cancer model with type 5 adenovirus vectors expressing murine angiostatin and IL-12: a role for combined anti-angiogenesis and immunotherapy.
Gyorffy S; Palmer K; Podor TJ; Hitt M; Gauldie J
J Immunol; 2001 May; 166(10):6212-7. PubMed ID: 11342643
[TBL] [Abstract][Full Text] [Related]
10. Immunogene therapy with interleukin-2-secreting fibroblasts for intracerebrally metastasizing breast cancer in mice.
Deshmukh P; Glick RP; Lichtor T; Moser R; Cohen EP
J Neurosurg; 2001 Feb; 94(2):287-92. PubMed ID: 11213967
[TBL] [Abstract][Full Text] [Related]
11. Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12.
Gambotto A; Tüting T; McVey DL; Kovesdi I; Tahara H; Lotze MT; Robbins PD
Cancer Gene Ther; 1999; 6(1):45-53. PubMed ID: 10078963
[TBL] [Abstract][Full Text] [Related]
12. Immunity to murine breast cancer cells modified to express MUC-1, a human breast cancer antigen, in transgenic mice tolerant to human MUC-1.
Carr-Brendel V; Markovic D; Ferrer K; Smith M; Taylor-Papadimitriou J; Cohen EP
Cancer Res; 2000 May; 60(9):2435-43. PubMed ID: 10811121
[TBL] [Abstract][Full Text] [Related]
13. Enhanced inhibition of tumour growth and metastasis, and induction of antitumour immunity by IL-2-IgG2b fusion protein.
Budagian V; Nanni P; Lollini PL; Musiani P; Di Carlo E; Bulanova E; Paus R; Bulfone-Paus S
Scand J Immunol; 2002 May; 55(5):484-92. PubMed ID: 11975760
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
Slos P; De Meyer M; Leroy P; Rousseau C; Acres B
Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452
[TBL] [Abstract][Full Text] [Related]
15. Induction of antitumor immunity by interleukin-2 gene-transduced mouse mammary tumor cells versus transduced mammary stromal fibroblasts.
Tsai SC; Gansbacher B; Tait L; Miller FR; Heppner GH
J Natl Cancer Inst; 1993 Apr; 85(7):546-53. PubMed ID: 8455201
[TBL] [Abstract][Full Text] [Related]
16. Combined CXC chemokine and interleukin-12 gene transfer enhances antitumor immunity.
Palmer K; Hitt M; Emtage PC; Gyorffy S; Gauldie J
Gene Ther; 2001 Feb; 8(4):282-90. PubMed ID: 11313802
[TBL] [Abstract][Full Text] [Related]
17. An adenoviral vector expressing interleukin-4 modulates tumorigenicity and induces regression in a murine breast-cancer model.
Addison C; Gauldie J; Muller W; Graham F
Int J Oncol; 1995 Dec; 7(6):1253-60. PubMed ID: 21552957
[TBL] [Abstract][Full Text] [Related]
18. Nature and potential of the reactive response to mouse mammary adenocarcinoma cells engineered with interleukin-2, interleukin-4 or interferon-gamma genes.
Musiani P; Modesti A; Brunetti M; Modica A; Vitullo P; Gulino A; Bosco MC; Colombo MP; Nanni P; Cavallo F
Nat Immun; 1994; 13(2-3):93-101. PubMed ID: 8173240
[TBL] [Abstract][Full Text] [Related]
19. Assessment of a combined, adenovirus-mediated oncolytic and immunostimulatory tumor therapy.
Bernt KM; Ni S; Tieu AT; Lieber A
Cancer Res; 2005 May; 65(10):4343-52. PubMed ID: 15899826
[TBL] [Abstract][Full Text] [Related]
20. In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector.
Toloza EM; Hunt K; Swisher S; McBride W; Lau R; Pang S; Rhoades K; Drake T; Belldegrun A; Glaspy J; Economou JS
Cancer Gene Ther; 1996; 3(1):11-7. PubMed ID: 8785705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
